CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Overweight at JPMorgan Chase & Co.

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Monday, MarketBeat Ratings reports. The brokerage presently has a $12.00 price target on the biotechnology company’s stock, up from their previous price target of $7.00. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 56.27% from the company’s previous close.

Several other equities analysts also recently commented on the stock. Barclays boosted their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Cantor Fitzgerald lifted their price target on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Piper Sandler increased their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, Guggenheim restated a “buy” rating and set a $10.00 price objective on shares of CytomX Therapeutics in a research report on Monday, March 9th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.38.

CytomX Therapeutics Stock Up 64.1%

NASDAQ CTMX traded up $3.00 during trading hours on Monday, reaching $7.68. The company’s stock had a trading volume of 85,620,283 shares, compared to its average volume of 4,775,381. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $8.21. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 19.34 and a beta of 2.44. The firm’s 50-day moving average price is $5.19 and its 200-day moving average price is $4.04.

Institutional Investors Weigh In On CytomX Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTMX. Goldman Sachs Group Inc. bought a new position in shares of CytomX Therapeutics during the 1st quarter valued at approximately $39,000. Woodline Partners LP bought a new stake in CytomX Therapeutics in the first quarter worth $1,054,000. Geode Capital Management LLC increased its position in CytomX Therapeutics by 103.4% during the second quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock valued at $3,963,000 after acquiring an additional 887,218 shares during the last quarter. Franklin Resources Inc. bought a new position in CytomX Therapeutics during the second quarter valued at $13,096,000. Finally, XTX Topco Ltd bought a new stake in shares of CytomX Therapeutics in the 2nd quarter worth about $277,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 dose-expansion data for varsetatug masetecan showed confirmed response rates of 32% (10 mg/kg Q3W) and 20% (8.6 mg/kg Q3W) with estimated PFS ~7 months and manageable grade 3 diarrhea (~10%); company is targeting mid-year FDA interactions to discuss a potential registrational trial and has initiated combination studies — this clinical readout is the primary catalyst for the stock move. CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
• Neutral Sentiment: Company published its 2025 financial results and a business update and hosted a conference call/slide deck providing context on the program timelines and cash/operating outlook — useful for judging runway and development timing. CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst previews and coverage highlighted the Q4 print and the clinical readout as the key near-term drivers; keep an eye on any updated analyst notes or revised models following the results. CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
• Negative Sentiment: Q4 results disappointed: GAAP loss of $0.22/sh vs. Zacks consensus loss of $0.08, and revenue of $0.66M missed expectations (~$7.33M). The financial miss raises near-term uncertainty around commercial/partner revenues and will push focus to cash burn and financing needs. CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.